vimarsana.com
Home
Live Updates
Roivant Reports Positive Topline Results from ADORING 1, the
Roivant Reports Positive Topline Results from ADORING 1, the
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10th consecutive... | May 16, 2023
Related Keywords
,
Eli Lilly ,
Stephanie Lee ,
Twitter ,
Exchange Commission ,
Dermavant Sciences ,
Dermavant Sciences Gmb ,
Roivant Sciences ,
Roivant Sciences Forward ,
Iqvia National Prescription Audit ,
Pabout Roivant Sciences ,
Dermavant Sciences Inc ,
Linkedin Dermavant Sciences ,
Securities Exchange ,
Securities Act ,
Securities Exchange Act ,
Risk Factors ,
Adverse Events ,
Prescribing Information ,
Atopic Dermatitis ,
All Rights ,
Prescription Audit ,
Roivant Sciences Ltd Stock Exchange ,
News ,
Information ,
Press Release ,
Adoring ,
Pet ,
The ,
Primary ,
End ,
Wall ,
Secondary ,
Consistent ,
Ith ,
Positive ,
Topline ,
Results ,
Rom ,
Hase ,
Trial ,
Eported ,
N ,
Parking ,
0th Roiv Bmg762791017 ,